(PACB) Pacific Biosciences of California, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PACB) Pacific Biosciences of California, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Pacific Biosciences of California, Inc. BCG Matrix shows how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, helping you assess growth and capital allocation potential. The page already includes a real preview of the analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Revio system, 2022 launch
Revio, launched in 2022, is Pacific Biosciences of California, Inc.'s flagship long-read platform and sits in the high-accuracy sequencing niche, where HiFi reads reach 99.9% accuracy. It is a Star because PACB is still driving placements and needs steady sales and application support to keep adoption moving.
SMRT Cells for Revio
SMRT Cells for Revio are consumables tied to every Revio run, so each instrument placement creates repeat orders. That makes revenue recurring and linked to the growing installed base, with one cell used per sequencing run. If Revio placements keep rising, this line can stay a Star because consumables usually scale faster than instruments.
HiFi library-prep and sequencing reagent bundles
HiFi library-prep and sequencing reagent bundles stay a Star because they sit at the core of Pacific Biosciences of California, Inc. HiFi workflows and are sold with instruments and consumables, so each install can lift recurring pull-through. Demand for highly accurate long reads is still rising, and that tight product linkage helps Pacific Biosciences of California, Inc. keep share high.
Large genome center workflows
Large genome centers remain a Star for Pacific Biosciences of California, Inc. because HiFi long reads deliver 99.9% base accuracy and suit high-throughput pangenome and rare-disease workflows. These flagship labs keep volume high, and demand stays strong as population-scale genomics grows in 2025.
- High-volume centers fit long-read scale
- Pangenome and rare-disease work lift demand
- HiFi accuracy supports complex genomes
Clinical research long-read workflows
Clinical research long-read workflows are a growth-heavy Star for Pacific Biosciences of California, Inc., because rare disease and oncology labs still lift adoption. Pacific Biosciences of California, Inc. reported 2024 revenue of $154.0 million, but it still posted a net loss, showing the segment needs more commercialization spend. Even so, long-read science is gaining share as clinical labs seek better structural-variant and haplotype resolution.
- Rare disease and oncology drive demand.
- Growth is strong, but profitability lags.
PacBio’s Revio and HiFi Are Driving Fast-Growth, Repeat Revenue
Stars at Pacific Biosciences of California, Inc. are Revio, HiFi consumables, and clinical long-read workflows because they sit in fast-growing demand areas and drive repeat pull-through. HiFi reads reach 99.9% accuracy, and the installed base keeps creating recurring SMRT Cell sales.
Large genome and rare-disease labs stay the main growth engines, with 2024 revenue at $154.0 million and continued heavy commercialization spend. The mix still looks like a Star: high share potential, but it needs scale to reach profit.
| Star item | Why it matters | Key number |
|---|---|---|
| Revio | Core growth platform | 99.9% HiFi accuracy |
| SMRT Cells | Recurring consumable pull-through | 1 cell per run |
| Company scale | Growth still outweighs profit | $154.0M revenue |
What is included in the product
Detailed Word Document
PacBio’s BCG matrix weighs SMRT sequencing growth stars against cash-draining niche products and legacy dogs.
Editable Excel File
Pacific Biosciences of California, Inc. BCG Matrix clarifies portfolio priorities fast, reducing strategic guesswork.
Reference Sources
Provides a traceable source trail for Pacific Biosciences of California, Inc., helping users verify claims quickly and make better decisions.
Cash Cows
Sequel IIe installed base, 2019
Sequel IIe still has a meaningful installed base, so it keeps bringing in recurring consumables and service revenue even as new-system growth slows. That makes it a mature cash cow versus Revio, which is the higher-growth platform. In PacBio’s latest reported results, recurring revenue remained a key support for cash generation.
Template preparation kits
Template preparation kits are classic Cash Cows for Pacific Biosciences of California, Inc. because they are routine consumables tied to installed instrument usage, not new market creation. That means demand is repeat-based and tends to track the active system base, so it supports steadier, lower-growth cash flow. PacBio’s own mix still leans on recurring workflow spend, which is the kind of revenue that usually outlasts one-time instrument sales.
Binding kits
Binding kits are a true Cash Cow for Pacific Biosciences of California, Inc. because every sequencing run needs the binding chemistry, so sales follow installed instruments and repeat usage. The line is mature, low-touch, and usually needs less promotion than new platforms. PacBio reported about $154 million in 2024 revenue, and this recurring consumable stream helps protect margins.
Sequencing kits for mature systems
Sequencing kits for mature systems are repeat-purchase consumables, so they sell every time a lab runs PacBio instruments and help build recurring revenue. In BCG terms, they act like cash cows: low-growth products with steady demand, tied to installed base usage and workflow execution.
- Repeat sales from routine runs
- Supports recurring revenue
- Low growth, steady cash flow
Service and maintenance contracts
Pacific Biosciences of California, Inc.'s service and maintenance contracts turn its installed base into steady, recurring revenue. In 2025, the company reported $40.0 million in service and other revenue, showing this line is smaller than instrument sales but much more predictable. That is classic cash-cow behavior: sticky demand, lower growth, and reliable cash flow.
- Recurring support from installed systems
- Lower growth, higher predictability
- Supports cash flow and retention
PacBio’s Recurring Service Revenue Keeps the Cash Flow Steady
Pacific Biosciences of California, Inc.'s cash cows are its installed-base consumables and service lines, led by mature kits and support tied to repeat sequencing runs. In 2025, service and other revenue was $40.0 million, showing a smaller but steadier cash source than new instrument sales.
| Cash cow | 2025 data | Why it fits |
|---|---|---|
| Service and other | $40.0 million | Recurring, sticky, predictable |
Full Version Awaits
Pacific Biosciences of California, Inc. Reference Sources
The Pacific Biosciences of California, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. It comes fully formatted and ready to use, with no watermark or placeholder content. Once purchased, you’ll get the complete version instantly for download, editing, or presentation.
Dogs
Sequel II legacy hardware
Sequel II legacy hardware is a Dog in Pacific Biosciences of California, Inc.’s BCG Matrix because newer platforms like Revio and Onso now carry demand. Buyers want higher throughput and lower cost per sample, so Sequel II has limited new-sales pull and weak pricing power. That puts it in low-growth, low-share territory and makes it a harvest-or-exit product.
Older consumables for retired platforms
Older reagent SKUs for retired Pacific Biosciences of California, Inc. platforms have weak demand as installed systems age out, so volumes keep shrinking. That makes inventory harder to balance and raises obsolescence risk. These lines usually absorb more management time than they return cash, so they fit Dogs in the BCG Matrix.
RS II and early PacBio platforms
RS II and early PacBio platforms are at the end of their product cycle, with little growth left and rising obsolescence risk, so they fit the Dog bucket. Pacific Biosciences of California, Inc. now focuses on newer Revio and Vega systems, which carry the growth and revenue mix. These legacy tools mainly support installed-base service, not future expansion.
Low-volume legacy software tools
Low-volume legacy software tools are a Dogs item for Pacific Biosciences of California, Inc. because newer HiFi workflows now drive the core value. In 2025, Pacific Biosciences of California, Inc. still relied mainly on instrument and consumable demand, while older analysis tools saw limited pull and weaker adoption. That makes this line small, slow, and less strategic.
- Low adoption
- Not the main revenue driver
- Shift to newer workflows
- Weak growth outlook
Obsolete accessories and demo stock
Obsolete accessories and demo stock fit the Dog category because they do not scale, and they usually tie up working capital without lifting future share. For Pacific Biosciences of California, Inc., these small lines can sit beside a core business that needs cash for R&D and commercial growth, not slow-moving inventory. The signal is simple: low strategic value, weak resale power, and limited repeat demand.
- Low growth, low share
- Tie up cash and storage
- Do not build moat
- Best cut or liquidate fast
PacBio’s Legacy Dogs: Sequel II and Old Reagents Lose Ground
Sequel II and RS II are Dogs in Pacific Biosciences of California, Inc.’s BCG Matrix: newer Revio and Onso systems now drive demand, while legacy units face shrinking sales and weak pricing power.
Older reagent SKUs and software for retired platforms also fit Dogs, with low adoption, rising obsolescence risk, and little strategic value.
| Dog item | Signal |
|---|---|
| Sequel II | Legacy, low share |
| Old reagents | Declining volume |
Question Marks
Onso short-read platform, 2023 launch
Onso, launched in 2023, gives Pacific Biosciences of California, Inc. a way into the much larger short-read market, where Illumina still posted about $4.3B in 2024 revenue. But Pacific Biosciences of California, Inc. is still a new entrant with low share, so this is a classic Question Mark: high upside, high execution risk.
Vega benchtop sequencing system
Vega is a Question Mark for Pacific Biosciences of California, Inc. because it targets smaller labs and broader access, but adoption is still early and unproven at scale. PacBio had to keep spending on sales and commercialization in 2025 to build demand, which is a classic sign of a new platform still fighting for share. If Vega wins even a small slice of the large benchtop sequencing market, it could matter; if not, it stays a cash-heavy bet.
Kinnex RNA and isoform kits
Kinnex RNA and isoform kits push Pacific Biosciences of California, Inc. beyond DNA into transcriptomics, opening a bigger market if labs adopt the workflow. PacBio’s 2025 revenue base is still small versus top life-science peers, so this line remains niche today. That mix of high upside and low share makes it a Question Mark.
Clinical diagnostics and IVD commercialization
Pacific Biosciences of California, Inc. fits Question Mark status in clinical diagnostics and IVD commercialization: the addressable IVD market is huge, but adoption is still gated by reimbursement, lab workflow fit, and scale-up. In 2025, PACB kept pushing regulated use cases, but clinical conversion remains slower than research use. That leaves high upside, but also high execution risk.
- Large market, slow adoption
- Reimbursement still key
- Workflow proof needed
- Scale decides payoff
Agricultural genomics solutions
Agricultural genomics is a real question mark for Pacific Biosciences of California, Inc.: long-read HiFi sequencing delivers >99.9% accuracy and strong structural-variant detection, which fits crop and livestock breeding well. But agrigenomics still trails research use in adoption, so PACB needs more field validation and commercial spend to win share.
Industry demand is rising as breeders use DNA data to speed trait selection, but the revenue pool is still small versus PACB’s broader research base. That means this segment can grow, yet it is not a near-term cash engine without heavier investment and partner-led scale.
- HiFi accuracy supports harder genome calls.
- Structural variants matter in crops.
- Adoption is still below research demand.
- More investment is needed to scale.
PacBio’s Big Bet: Early Wins, Real Risk
Question Marks at Pacific Biosciences of California, Inc. are Onso, Vega, Kinnex RNA, clinical diagnostics, and agrigenomics: each targets a large market, but share is still low and adoption is early. PacBio’s 2025 push into these areas needs more sales spend, validation, and workflow fit to turn upside into revenue. The payoff is real, but so is execution risk.
| Area | Signal |
|---|---|
| Onso | 2023 launch |
| Vega | Early adoption |
| Kinnex RNA | Niche today |
| Clinical/IVD | Reimbursement gate |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.